Evidence map›Paper›PMID 39912659›Full record

Trial reportAntimicrobial agents and chemotherapy2025

Pharmacokinetics and bioequivalence of a molnupiravir tablet formulation compared with the molnupiravir capsule formulation in healthy adult participants-a randomized, open-label, three-period, crossover study.

Julie L Fiore, Yoon Jin, Tycho Heimbach, Shruti R Patel, Tian Zhao, Catherine Z Matthews, Sandra Pagnussat, Brian M Maas, Mickie H Cheng, S Aubrey Stoch

Registry-linked trialAbstract readRandomized Controlled TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06615869 (A Study to Evaluate the Pharmacokinetics and Definitive Bioequivalence of Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06615869 phase1completednot on this map

A Study to Evaluate the Pharmacokinetics and Definitive Bioequivalence of Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2023 to 2023Enrolled64ConditionsHealthyArmsMolnupiravir
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Julie L FioreMerck & Co., Inc., Rahway, New Jersey, USA.
Yoon JinMerck & Co., Inc., Rahway, New Jersey, USA.
Tycho HeimbachMerck & Co., Inc., Rahway, New Jersey, USA.
Shruti R PatelMerck & Co., Inc., Rahway, New Jersey, USA.
Tian ZhaoMerck & Co., Inc., Rahway, New Jersey, USA.
Catherine Z MatthewsMerck & Co., Inc., Rahway, New Jersey, USA.
Sandra PagnussatQPS, Miami, Florida, USA.
Brian M MaasMerck & Co., Inc., Rahway, New Jersey, USA.ORCID 0000-0002-2410-4379
Mickie H ChengMerck & Co., Inc., Rahway, New Jersey, USA.ORCID 0009-0003-5735-1821
S Aubrey StochMerck & Co., Inc., Rahway, New Jersey, USA.ORCID 0000-0001-5620-7092

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molnupiravir, a prodrug of β-D-N

Indexed as

Antiviral AgentsCytidineHydroxylaminesAdministration, OralAdultArea Under CurveCapsulesCOVID-19 Drug TreatmentCross-Over StudiesFemaleHealthy VolunteersHumansMaleMiddle AgedProdrugsTabletsAntiviral AgentsCapsulesCytidineHydroxylaminesmolnupiravirProdrugsTabletsantiviralbioequivalenceCOVID-19pharmacokinetics

Identifiers

PMID39912659
PMCPMC11881578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.